
In a decisive ruling, Millennium Pharmaceuticals and its counsel Cohausz & Florack secured validation of the Velcade formulation patents before Germany’s Federal Court of Justice, overturning challenges from three generic drug makers.
Federal Court upholds EP 2 251 344 B1 and EP 3 078 667 B1
The court affirmed the validity of patents EP 2 251 344 B1 and EP 3 078 667 B1, which protect a boronic-acid formulation of bortezomib, the active ingredient in Velcade. The decision confirms a 2024 first-instance judgment that the patents were neither unduly extended nor insufficiently disclosed.
Both patents, owned by the United States, are licensed to Millennium, a Takeda Oncology subsidiary, with Janssen-Cilag handling distribution in Germany. Although the patents expired in January 2022, the company continues to pursue damages against generic competitors across Europe.
Generic firms Zentiva, Ratiopharm and Betapharm filed nullity suits in April 2024. The Federal Patent Court dismissed those actions, finding the subject matter novel and inventive. The appellate division of the Federal Court of Justice, chaired by Judge Klaus Bacher, rejected the appeals and ordered the challengers to bear all costs, including those of the intervener Millennium.
Confidentiality of clinical trials at issue
A central question was whether data from clinical trials required for marketing authorisation could be treated as prior art that would invalidate the patents. The claimants argued that trial sites had not kept the studies sufficiently confidential.
The court noted that medical staff were bound by confidentiality obligations and that no evidence showed outsiders could extract meaningful information from the trials. It highlighted that each trial vial contained only 2.5 mg of the active substance, insufficient for reliable analysis, and that a skilled person would not have been prompted to lyophilise bortezomib with excess D-mannitol.
Research by JUVE Patent indicates the Federal Court of Justice assumes a duty of confidentiality exists during trials and requires concrete proof of breach before granting a nullity declaration.
In parallel infringement proceedings, the Regional Court in Düsseldorf dismissed the company’s claims, citing a lack of standing because the United States, as patentee, retained the right to issue further exclusive licences—an arrangement incompatible with an exclusive licence under German law. An appeal is pending before the Düsseldorf Higher Regional Court.
Other European jurisdictions, including Italy and Spain, are seeing related damages actions, while the European Patent Office’s Boards of Appeal upheld EP 3 078 667 in a limited form in mid-2024.
Related Post: Agfa patent largely revoked on appeal
The litigation team featured Cohausz & Florack attorneys Arwed Burrichter and Natalie Kirchhofer, supported by Christian Rohnke and Herbert Smith Freehills’ Ina vom Feld. Opposing counsel included ZSP Patentanwälte for Betapharm, Bird & Bird representatives for Zentiva, and Graf von Stosch attorneys for Ratiopharm.
During the hearing, the court also addressed the procedural costs, confirming that the appellants must cover both appeal expenses and those incurred by the intervener Millennium, reinforcing the financial stakes of patent disputes in the pharmaceutical sector.
Implications for patent law and clinical-trial confidentiality
The case has broader implications for pharmaceutical patents. It asks when clinical trials required for marketing authorisation can count as prior art that bars later patent protection.
Ongoing and pending proceedings across Europe
Separate damages actions continue in Italy and Spain, where the same formulation patents are being enforced against local generic manufacturers. Those cases follow the same procedural posture, with the American patent holder maintaining exclusive licensing arrangements that shape standing arguments before national courts.
That hearing will determine whether the exclusive-licence reservation by the American owner precludes the licensee from pursuing infringement claims under German law.
Market analysts estimate that the therapeutic segment encompassing bortezomib-based treatments commands roughly $25.88 billion worldwide, with steady growth projected over the coming years. The financial magnitude highlights the strategic importance of securing patent protection for formulation innovations.
In the French proceedings, the Paris Judicial Court’s partial judgment confirmed that the licence agreement permits the licensee to sue in its own name, regardless of exclusivity status. The court is presently quantifying damages linked to price reductions that occurred after generic entry.
That limited affirmation restricts the scope of protection but still provides a basis for national enforcement actions.
The United States patent holder relied on counsel from Hoyng ROKH Monegier in both the Düsseldorf and Paris cases.
